The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 07, 2025

Filed:

Aug. 05, 2020
Applicant:

The United States of America, As Represented BY the Secretary, Dept. of Health and Human Services, Bethesda, MD (US);

Inventors:

Richard W. Childs, Bethesda, MD (US);

Mattias C. V. Carlsten, Bethesda, MD (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2015.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07K 14/715 (2006.01); C07K 14/735 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01);
U.S. Cl.
CPC ...
C07K 16/2896 (2013.01); A61K 39/39558 (2013.01); A61K 39/4613 (2023.05); A61K 39/464402 (2023.05); A61K 39/464421 (2023.05); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 14/70535 (2013.01); C07K 14/7158 (2013.01); C07K 16/2887 (2013.01); C12N 5/0646 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); A61K 2039/57 (2013.01); A61K 2039/572 (2013.01); A61K 2239/48 (2023.05); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/732 (2013.01); C12N 2501/21 (2013.01); C12N 2501/2302 (2013.01); C12N 2501/599 (2013.01); C12N 2510/00 (2013.01);
Abstract

Disclosed herein are modified NK cells, compositions comprising modified NK cells, and methods for treating a tumor or hyperproliferative disease in a subject. In some embodiments, the modified NK cells include NK cells including a heterologous nucleic acid molecule encoding a CD16 protein comprising a valine at amino acid position 158 (CD16-V158), a heterologous nucleic acid molecule encoding a CCR7 protein, or both. In some embodiments, methods include treating a subject with a tumor by administering a composition comprising an anti-cancer monoclonal antibody and administering a composition comprising the modified NK cells to the subject. Also disclosed are methods of making modified NK cells by obtaining a population of NK cells from a subject and transfecting the population of NK cells with a heterologous nucleic acid molecule encoding CD16-V158, a heterologous nucleic acid molecule encoding a CCR7 protein, or both.


Find Patent Forward Citations

Loading…